| |
Drug use
|
Beta (95% CI)
|
P-value
|
|---|
|
Arbidol
|
Early use vs No use
|
− 5.2 (− 7.5, − 3.0)
|
4.0E−06
|
|
Late use vs No use
|
1.4 (− 0.1, 2.9)
|
0.074
|
|
Overall use vs No use
|
− 0.1 (− 1.8, 1.6)
|
0.91
|
|
Ribavirin
|
Early use vs No use
|
− 0.3 (− 2.2, 1.59)
|
0.75
|
|
Late use vs No use
|
3.0 (1.1, 4.8)
|
0.0018
|
|
Overall use vs No use
|
2.1 (0.5, 3.7)
|
0.01
|
|
IFN-α
|
Early use vs No use
|
− 0.2 (− 2.0, 1.6)
|
0.82
|
|
Late use vs No use
|
2.2 (− 0.1, 4.4)
|
0.06
|
|
Overall use vs No use
|
1.4 (− 0.6, 3.4)
|
0.17
|
|
Lopinavir–ritonavir
|
Early use vs No use
|
4.7 (3.1, 6.2)
|
1.8E−08
|
|
Late use vs No use
|
7.5 (5.4, 9.6)
|
1.7E−11
|
|
Overall use vs No use
|
4.1 (2.3, 5.9)
|
1.4E−05
|
- Association test between patients’ recovery time length against where early drug use or not; late drug use or not. Multivariate linear regression model was used and risk factors and confounding factors were adjusted
